Edition:
India

ADMA Biologics Inc (ADMA.OQ)

ADMA.OQ on NASDAQ Stock Exchange Capital Market

4.70USD
1:30am IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.70
Open
$4.72
Day's High
$4.72
Day's Low
$4.60
Volume
256,058
Avg. Vol
197,507
52-wk High
$6.96
52-wk Low
$2.08

Latest Key Developments (Source: Significant Developments)

Adma Biologics Prices Public Offering Of Common Stock At $4.00 Per Share
Friday, 17 May 2019 

May 17 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 11.3 MILLION COMMON SHARES PRICED AT $4.00PER SHARE.  Full Article

Adma Biologics Announces Proposed $45 Million Public Offering Of Common Stock
Thursday, 16 May 2019 

May 15 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS ANNOUNCES PROPOSED $45 MILLION PUBLIC OFFERING OF COMMON STOCK.ADMA BIOLOGICS - TO USE NET PROCEEDS TO SUPPORT COMMERCIAL LAUNCH OF ASCENIV ANTICIPATED DURING H2, FOR COMMERCIAL RELAUNCH OF BIVIGAM, AMONG OTHERS.  Full Article

ADMA Biologics Reports Q1 Loss Per Share $0.28
Thursday, 9 May 2019 

May 8 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.28.Q1 EARNINGS PER SHARE ESTIMATE $-0.32 -- REFINITIV IBES DATA.Q1 REVENUE $3.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $3.2 MILLION.  Full Article

Adma Biologics Elects To Draw-Down $27.5 Mln In Capital From Existing Perceptive Advisors Credit Agreement
Friday, 3 May 2019 

May 3 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS ELECTS TO DRAW-DOWN $27.5 MILLION IN CAPITAL FROM EXISTING PERCEPTIVE ADVISORS CREDIT AGREEMENT.ADMA BIOLOGICS INC - ELECTED TO DRAW-DOWN $27.5 MILLION FROM ITS EXISTING CREDIT AGREEMENT WITH PERCEPTIVE ADVISORS.ADMA BIOLOGICS - CO, PERCEPTIVE ADVISORS ENTERED AMENDMENT, PROVIDING FOR AN UPSIZED, FUNDING TRANCHE COMMITMENT UPON GETTING FDA APPROVAL OF BIVGAM.ADMA BIOLOGICS INC - ADDITIONAL $12.5 MILLION COMMITMENT WILL BE AVAILABLE TO ADMA AT ITS SOLE OPTION FOLLOWING FDA APPROVAL UNTIL MARCH 31, 2020.  Full Article

FDA Approves ADMA Biologic's Immunodeficiency Disease Treatment Asceniv
Tuesday, 2 Apr 2019 

April 1 (Reuters) - ADMA Biologics Inc ::FDA APPROVES ASCENIV, A NOVEL INTRAVENOUS IMMUNE GLOBULIN.COMPANY ANTICIPATES HAVING PRODUCT AVAILABLE FOR COMMERCIAL LAUNCH DURING SECOND HALF OF 2019.ADMA BIOLOGICS - ASCENIV APPROVED FOR USE IN TREATMENT OF PRIMARY HUMORAL IMMUNODEFICIENCY DISEASE IN ADULTS, ADOLESCENTS (12 TO 17 YEARS OF AGE).FDA APPROVAL TRIGGERS FUNDING UP TO $27.5 MILLION FROM EXISTING CREDIT FACILITY WITH PERCEPTIVE ADVISORS.ASCENIV PIVOTAL PHASE III CLINICAL STUDY FOLLOWED FDA GUIDANCE FOR TREATMENT OF PATIENTS WITH PI.  Full Article

ADMA Biologics Enters Into $72.5 Mln Loan Facility With Perceptive Advisors
Tuesday, 12 Feb 2019 

Feb 12 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS ENTERS INTO $72.5 MILLION LOAN FACILITY WITH PERCEPTIVE ADVISORS.ADMA BIOLOGICS INC - PERCEPTIVE CREDIT AGREEMENT HAS AN INTEREST ONLY TERM WITH A MATURITY DATE OF MARCH 1, 2022.ADMA BIOLOGICS INC - NEW PERCEPTIVE LOAN FACILITY DOES NOT INCLUDE ANY BACK-END FEES.  Full Article

Adma Biologics Provides Regulatory Update For Bivigam
Thursday, 11 Oct 2018 

Oct 11 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS PROVIDES REGULATORY UPDATE FOR BIVIGAM®.ADMA BIOLOGICS INC - FDA HAS ESTABLISHED A TARGET ACTION DATE OF DECEMBER 18, 2018 FOR PAS UNDER PRESCRIPTION DRUG USER FEE ACT.ADMA BIOLOGICS - FDA CONSIDERS CO'S RECENT RESPONSE TO AGENCY'S INFORMATION REQUEST RELATED TO PRIOR APPROVAL SUPPLEMENT SUBMISSION A MAJOR AMENDMENT.ADMA BIOLOGICS - FDA COMMUNICATION RECEIVED BY CO HAS NO IMPACT ON OTHER ONGOING AGENCY INTERACTIONS OR TO RECENT RI-002 BLA RESUBMISSION.ADMA BIOLOGICS - FDA HAS INFORMED CO THAT THEY REQUIRE MORE 2 MONTHS TO COMPLETE THEIR REVIEW OF PAS SUBMITTED IN JUNE 2018 TO AMEND BLA FOR BIVIGAM.  Full Article

ADMA Biologics Reports FDA Compliance Status For Manufacturing Facility
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS REPORTS FDA COMPLIANCE STATUS FOR ITS MANUFACTURING FACILITY HAS IMPROVED.ADMA BIOLOGICS INC - RI-002'S BIOLOGICS LICENSE APPLICATION RESUBMISSION TARGETED FOR Q3 2018.ADMA BIOLOGICS INC - FDA INSPECTION DATABASE CONFIRMS VAI STATUS OF BOCA RATON, FL FACILITY.ADMA BIOLOGICS INC - WILL ANNOUNCE RELATED INFORMATION PERTAINING TO RI-002'S BLA FILING WHEN COMPANY RECEIVES CORRESPONDENCE FROM FDA.  Full Article

ADMA Biologics Q1 Loss Per Share $0.39
Tuesday, 15 May 2018 

May 14 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.39.Q1 EARNINGS PER SHARE VIEW $-0.31 -- THOMSON REUTERS I/B/E/S.Q1 REVENUE ROSE 54 PERCENT TO $4.0 MILLION.Q1 REVENUE VIEW $6.2 MILLION -- THOMSON REUTERS I/B/E/S.ADMA BIOLOGICS - AT MARCH 31, 2018, ADMA HAD CASH AND CASH EQUIVALENTS OF $26.1 MILLION, AS COMPARED TO $43.1 MILLION AT DECEMBER 31, 2017.  Full Article

ADMA Biologics Retires About 8.6 Million Shares Previously Issued to Biotest
Monday, 14 May 2018 

May 14 (Reuters) - ADMA Biologics Inc ::ADMA BIOLOGICS INC - RETIRES APPROXIMATELY 8.6 MILLION SHARES PREVIOUSLY ISSUED TO BIOTEST PHARMACEUTICALS CORPORATION AND ITS FORMER PARENT, BIOTEST AG.ADMA BIOLOGICS - BPC WILL TRANSFER ABOUT 8.6 MILLION SHARES OF ADMA'S NON-VOTING COMMON STOCK BACK TO ADMA.ADMA BIOLOGICS - RETIREMENT OF ABOUT 8.6 MILLION SHARES FOR WAIVER AND RELEASE OF CERTAIN ADMA RIGHTS UNDER AGREEMENT, DATED AS OF JANUARY 21, 2017.ADMA BIOLOGICS INC - BPC WILL WAIVE AND TERMINATE ALL RIGHTS TO NAME A DIRECTOR AND OBSERVER TO ADMA'S BOARD OF DIRECTORS.ADMA BIOLOGICS - ADMA WILL TERMINATE RIGHTS TO REPURCHASE 2 ADMA BIOCENTERS WHICH CO HAD PREVIOUSLY AGREED TO TRANSFER TO BPC ON JANUARY 1, 2019..  Full Article

UPDATE 1-FDA declines to approve re-launch of ADMA Biologics' Bivigam

Dec 19 The U.S. Food and Drug Administration (FDA)on Wednesday declined to approve ADMA Biologics Inc's application to re-launch its immune deficiency treatment Bivigam, the company said.